McClellan back at FDA
This article was originally published in The Tan Sheet
Executive Summary
Brookings Institution's Engelberg Center for Healthcare Reform Director Mark McClellan returns to his FDA bailiwick as chairman of the Reagan-Udall Foundation. The former FDA commissioner will lead the private organization established by the FDA Amendments Act to advance the agency's Critical Path initiative and identify unmet scientific needs. Other Reagan-Udall board members announced Nov. 16 include representatives from Genzyme and Johnson & Johnson. House Agriculture-FDA Appropriations Chairwoman Rosa DeLauro, D-Conn., has requested FDA stop activities related to the creation of the foundation until the agency addresses issues of industry influence (1"The Tan Sheet" Nov. 12, 2007, In Brief)...
You may also be interested in...
Reagan-Udall pushback
Rep. Rosa DeLauro, D-Conn., wants FDA to halt efforts to establish the Reagan-Udall Foundation, a non-profit advisory body established by the recently enacted FDA Amendments Act. "The potential for pressure on FDA staff from Reagan-Udall Foundation-endorsed research is enormous," the chair of the House subcommittee overseeing FDA's budget writes in a Nov. 1 letter to Commissioner Andrew von Eschenbach. The foundation, to be funded from donations, patent revenue and FDA's budget, is tasked to work with FDA on its critical path initiative and other product development efforts (1"The Tan Sheet" Oct. 8, 2007, In Brief). By law, four members of the yet-unnamed 14-person foundation board must be from the drug, device, food, cosmetic and biotech industries...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.